Geovax presents gedeptin® clinical data at the aacr-ahns head and neck cancer conference

Atlanta, ga, july 10, 2023 (globe newswire) -- via newmediawire – geovax labs, inc. (nasdaq: govx), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, announced today the presentation of phase 1/2 clinical trial data for geovax's gene therapy candidate, gedeptin® at the american association for cancer research (aacr) and the american head and neck society (ahns) joint head and neck cancer conference in montrÉal, qc, canada. the presentation, titled “phase 1/ 2 study of ad/pnp with fludarabine for the treatment of head neck squamous cell carcinoma (hnscc)”, describes the evaluation of gedeptin as an experimental therapy for refractory solid tumors.
GOVX Ratings Summary
GOVX Quant Ranking